Both metformin and exenatide increased bone cell activity at defect sites in non-diabetic rats, suggesting potential bone healing benefits.
p = 0.007Significant increase in both osteoblast and osteoclast numbers in drug-treated groups vs. control
What the researchers found
Metformin and exenatide significantly increased osteoblast and osteoclast numbers at bone defect sites (p=0.007 for both) without affecting overall bone volume.
Why it matters
If diabetes drugs can enhance bone healing, this could benefit patients with fractures or bone defects, particularly those already taking these medications.
The numbers in context
- 27 rats in 3 groups of 9
- Metformin dose: 100 mg/kg/day orally
- Exenatide dose: 3 microg/kg/day intraperitoneally
- Osteoblast count: significantly higher in both drug groups (p=0.007)
- Osteoclast count: significantly higher in both drug groups (p=0.007)
- Bone volume, density, integration: no significant differences
How the study worked
Preclinical study in 27 female Wistar rats with cranial bone defects, analyzed by micro-CT and histology.
Who was studied
N=27 female albino Wistar rats with craniotomy defects, divided into metformin, exenatide, and control groups. Non-diabetic.
What this study cannot tell us
Animal study with small groups. No significant difference in bone volume or density. Short observation period.
How to read the evidence
Small preclinical study. Interesting but preliminary; no bone volume benefit seen.
When this study was published
Published in 2025.
The bigger picture
The bone-modulating effects of GLP-1 agonists and metformin add to the growing list of benefits beyond glucose control for these widely used drugs.
Questions still open
- Would longer treatment show differences in bone volume and density?
- Could these drugs be used clinically to enhance fracture healing?
Common questions
Can diabetes drugs help heal broken bones?
Does this apply to people who are not diabetic?
Read the original research
Osteogenic effects of metformin and exenatide on bone regeneration in non-diabetic rats: A Micro-CT and histological study.
Journal of oral and maxillofacial pathology : JOMFP, 29(3), 352-359
Citation
Ozturk, Hasan; Simsek, Neslihan; Akinci, Levent; Ozgocmen, Meltem; Yigit, Dilek Helvacioglu. (2025). Osteogenic effects of metformin and exenatide on bone regeneration in non-diabetic rats: A Micro-CT and histological study.. Journal of oral and maxillofacial pathology : JOMFP, 29(3), 352-359. https://doi.org/10.4103/jomfp.jomfp_4_25